Clinical Trial Update: Multi-Center Study to Evaluate the Efficacy and Safety of Sildenafil Cream (3.6%) in Premenopausal Patients With Female Sexual Arousal Disorder [Phase 2]

View source ↗

Summary

Phase 2 multi-center trial evaluating the efficacy and safety of Sildenafil Cream (3.6%) for female sexual arousal disorder in premenopausal patients.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Female Sexual Arousal Disorder

Drugs mentioned

• Sildenafil Cream, 3.6% (sildenafil)

Snippet

Sponsor: Strategic Science & Technologies, LLC | Conditions: Female Sexual Arousal Disorder | Phase 2 | Status: UNKNOWN